{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:49:12Z","timestamp":1787636952334,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.neuroscience.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:28:05Z","timestamp":1780842485000},"page":"136-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Current genetic approaches for the treatment of prion diseases"],"prefix":"10.1016","volume":"610","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2359-6708","authenticated-orcid":false,"given":"Dimitrios","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Dafou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Sklaviadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8759-8962","authenticated-orcid":false,"given":"Konstantinos","family":"Xanthopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.06.004_b0005","doi-asserted-by":"crossref","unstructured":"Prusiner, S., Prusiner, S.B., 1997. Nobel Lecture.","DOI":"10.1016\/S0294-3506(99)80368-8"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1743-422X-8-559","article-title":"An overview of human prion diseases","volume":"8","author":"Imran","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00401-010-0735-5","article-title":"Molecular pathology of human prion disease","volume":"121","author":"Wadsworth","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1152\/physrev.00006.2009","article-title":"Prions: protein aggregation and infectious diseases","volume":"89","author":"Aguzzi","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00401-012-1002-8","article-title":"Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA","volume":"124","author":"Parchi","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0030","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3201\/eid2012.140214","article-title":"Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties","volume":"20","author":"Diack","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0035","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000160117.56690.B2","article-title":"Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada","volume":"64","author":"Ladogana","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0040","unstructured":"Creutzfeldt-Jakob Disease (CJD) Surveillance Update 2024 - GOV.UK Available online: https:\/\/www.gov.uk\/government\/publications\/creutzfeldt-jakob-disease-cjd-surveillance-update-2024\/creutzfeldt-jakob-disease-cjd-surveillance-update-2024 (accessed on 6 May 2026)."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0045","unstructured":"State Department of Health - DCHS - Communicable Disease Epidemiology, W. Human Prion Diseases Transmissible Spongiform Encephalopathies (TSE) Including Creutzfeldt-Jakob Disease (CJD)."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0050","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/0092-8674(93)90360-3","article-title":"Mice devoid of PrP are resistant to scrapie","volume":"73","author":"B\u00fceler","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/emboj\/21.3.202","article-title":"Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration","volume":"21","author":"Mallucci","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0060","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"4","author":"Raymond","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.ejhg.5201544","article-title":"Prion disease genetics","volume":"14","author":"Mead","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5169","article-title":"Quantifying prion disease penetrance using large population control cohorts","volume":"8","author":"Minikel","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/380639a0","article-title":"Altered circadian activity rhythms and sleep in mice devoid of prion protein","volume":"380","author":"Tobler","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4161\/pri.1.2.4346","article-title":"The prion protein knockout mouse: a phenotype under challenge","volume":"1","author":"Steele","year":"2007","journal-title":"Prion"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/37783","article-title":"The cellular prion protein binds copper in vivo","volume":"390","author":"Brown","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jnr.10118","article-title":"Lack of prion protein expression results in a neuronal phenotype sensitive to stress","volume":"67","author":"Brown","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1471-4159.2001.00028.x","article-title":"Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein","volume":"76","author":"Wong","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nn.2483","article-title":"Axonal prion protein is required for peripheral myelin maintenance","volume":"13","author":"Bremer","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.imbio.2015.07.017","article-title":"Prion protein-deficient mice exhibit decreased CD4 T and LTi cell numbers and impaired spleen structure","volume":"221","author":"Kim","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.20151610","article-title":"Strictly co-isogenic C57BL\/6J-prnp-\/- mice: a rigorous resource for prion science","volume":"213","author":"Nuvolone","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0115","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature19312","article-title":"The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6","volume":"536","author":"K\u00fcffer","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nn.2238","article-title":"Olfactory behavior and physiology are disrupted in prion protein knockout mice","volume":"12","author":"Le Pichon","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbr.2005.02.003","article-title":"Altered behavioural response to acute stress in mice lacking cellular prion protein","volume":"162","author":"Nico","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.nbd.2005.01.001","article-title":"Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons","volume":"19","author":"Criado","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0135","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","author":"Minikel","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature20415","article-title":"Mammalian prions and their wider relevance in neurodegenerative diseases","volume":"539","author":"Collinge","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1871526510909010081","article-title":"Recent advances in prion chemotherapeutics","volume":"9","author":"Sim","year":"2009","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1324702","article-title":"New implications for prion diseases therapy and prophylaxis","volume":"17","author":"Liu","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Ha\u00efk","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0160","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1468-1331.2008.02108.x","article-title":"Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK","volume":"15","author":"Bone","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial","volume":"8","author":"Collinge","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1474-4422(22)00082-5","article-title":"Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt\u2013Jakob disease: evaluation of a first-in-human treatment programme","volume":"21","author":"Mead","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0175","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14728222.2020.1782384","article-title":"Novel regulators of PrP C expression as potential therapeutic targets in prion diseases","volume":"24","author":"Colini Baldeschi","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0180","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41591-024-03466-w","article-title":"In vivo base editing extends lifespan of a humanized mouse model of prion disease","volume":"31","author":"An","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0185","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4103\/NRR.NRR-D-24-00181","article-title":"Therapeutic targeting of cellular prion protein: toward the development of dual mechanism anti-prion compounds","volume":"20","author":"Masone","year":"2025","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrg.2015.3","article-title":"RNA mis-splicing in disease","volume":"17","author":"Scotti","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0200","first-page":"5","article-title":"Antisense oligonucleotides","author":"Scoles","year":"2019","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102237","article-title":"Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing","volume":"35","author":"Aguti","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-0716-0771-8_2","article-title":"Development and clinical applications of antisense oligonucleotide gapmers","volume":"2176","author":"Chan","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0225","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098496","article-title":"Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected mice","volume":"9","author":"Ahn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0235","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1073\/pnas.1901947116","article-title":"Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development","volume":"116","author":"Vallabh","year":"2019","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0240","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1212\/WNL.0000000000007745","article-title":"Age at onset in genetic prion disease and the design of preventive clinical trials","volume":"93","author":"Minikel","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0245","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1074\/mcp.RA119.001702","article-title":"Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry","volume":"18","author":"Minikel","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0250","doi-asserted-by":"crossref","unstructured":"Vallabh, S.M., Mortberg, M.A., Allen, S.W., Kupferschmid, A.C., Kivis\u00e4kk, P., Hammerschlag, B.L., Bolling, A., Trombetta, B.A., Devitte-McKee, K., Ford, A.M., et al., 2023. Biomarker changes preceding symptom onset in genetic prion disease. medRxiv, doi:10.1101\/2023.12.18.23300042.","DOI":"10.1101\/2023.12.18.23300042"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0255","unstructured":"Study Details | NCT06153966 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 | ClinicalTrials.Gov Available online: https:\/\/clinicaltrials.gov\/study\/NCT06153966 (accessed on 6 May 2026)."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1130925","article-title":"A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides","volume":"14","author":"Linninger","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1414658","article-title":"Antisense oligonucleotides and their applications in rare neurological diseases","volume":"18","author":"McDowall","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0270","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0275","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2174\/1570159X19666210402104054","article-title":"SiRNA therapeutics: future promise for neurodegenerative diseases","volume":"19","author":"Amiri","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0280","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.3390\/ijms26083456","article-title":"Recent update on SiRNA therapeutics","volume":"26","author":"Ebenezer","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrn1584","article-title":"Rational targeting for prion therapeutics","volume":"6","author":"Mallucci","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0290","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular MicroRNA\/Short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0295","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102057","article-title":"Efficacy and safety of a SOD1-targeting artificial MiRNA delivered by AAV9 in mice are impacted by MiRNA scaffold selection","volume":"34","author":"Chen","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0310","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0315","doi-asserted-by":"crossref","DOI":"10.1177\/21593337251371594","article-title":"Cell type distribution of intrathecal antisense oligonucleotide activity in deep brain regions of non-human primates","author":"Frei","year":"2025","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0320","doi-asserted-by":"crossref","first-page":"14051","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of Cynomolgus Macaques following delivery of AAV9 into the Cisterna Magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0325","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0330","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1172\/JCI29236","article-title":"Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice","volume":"116","author":"Pfeifer","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0335","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ymthe.2005.11.012","article-title":"Lentiviral vectors for use in the central nervous system","volume":"13","author":"Jakobsson","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0340","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.900610","article-title":"Lipid-based nanoparticles and RNA as innovative neuro-therapeutics","volume":"13","author":"Tsakiri","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0345","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/1061186X.2023.2247583","article-title":"The battle of lipid-based nanocarriers against blood-brain barrier: a critical review","volume":"31","author":"Abla","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0350","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1073\/pnas.0802759105","article-title":"Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease","volume":"105","author":"White","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0355","doi-asserted-by":"crossref","unstructured":"Gentile, J.E., Corridon, T.L., Serack, F.E., Echeverria, D., Kennedy, Z.C., Gallant-Behm, C.L., Hassler, M.R., Kinberger, G.A., Kelemen, M.N., Kamath, N.G., et al., 2024. Divalent SiRNA for prion disease, doi:10.1101\/2024.12.05.627039.","DOI":"10.1101\/2024.12.05.627039"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0360","unstructured":"Study Details | NCT07444580 | PrP-Targeting SiRNA Safety & Mechanism Study | ClinicalTrials.Gov Available online: https:\/\/clinicaltrials.gov\/study\/NCT07444580?cond=Prion%20Diseases&intr=siRNA&viewType=Card&rank=1 (accessed on 29 April 2026)."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0365","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag287","article-title":"Divalent SiRNA for prion disease","volume":"54","author":"Gentile","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2022.1054069","article-title":"Strategies to improve safety profile of AAV vectors","volume":"2","author":"Suoranta","year":"2022","journal-title":"Front. Mol. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0375","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/epi-2023-0281","article-title":"CRISPR-based epigenome editing: mechanisms and applications","volume":"15","author":"Fadul","year":"2023","journal-title":"Epigenomics"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0380","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114594","article-title":"CRISPR-Cas9-based knockout of the prion protein and its effect on the proteome","volume":"9","author":"Mehrabian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0390","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nu\u00f1ez","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0395","article-title":"In vitro selection of engineered transcriptional repressors for targeted epigenetic silencing","volume":"2023","author":"Migliara","year":"2023","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0400","unstructured":"Chou, S.-W., Parman, T., Ledeboer, A., Marlen, K., Ojala, D., Tiffany, M., Pokatayev, M.A., Howard, M., Lenz, K., Guzman, K., et al., 2024. Single intravenous treatment with zinc finger repressor leads to brain-wide reduction of prion in nonhuman primates and significantly prolongs survival in the RML mouse model."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0405","article-title":"Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor","volume":"384","author":"Neumann","year":"2024","journal-title":"Science (1979)"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0410","unstructured":"Chou, S.-W., Marlen, K., Tiffany, M., Dunn, P., Houlihan, G., Pokatayev, M.A., Cisbani, G., Peters, F., Hu, J., Fieblinger, T., et al., 2025. Sustained brain-wide reduction of prion via zinc finger repressors in mice and nonhuman primates as a potential one-time treatment for prion disease."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0415","doi-asserted-by":"crossref","unstructured":"Chou, S.-W., Mortberg, M.A., Marlen, K., Ojala, D.S., Parman, T., Howard, M., DeSouza-Lenz, K., Lian, Y., Mehrabian, M., Tiffany, M., et al., 2025. Zinc finger repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice.","DOI":"10.1101\/2025.03.05.636713"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0420","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nbt1271","article-title":"Production of cattle lacking prion protein","volume":"25","author":"Richt","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0425","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0430","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0435","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0440","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs CRISPR-Cas9 targeting accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0445","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41587-020-0517-0","article-title":"An engineered ScCas9 with broad PAM range and high specificity and activity","volume":"38","author":"Chatterjee","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0450","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a P53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0455","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0460","first-page":"653","article-title":"Genome editing: past, present, and future","volume":"90","author":"Carroll","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0465","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","article-title":"Human germline genome editing","volume":"101","author":"Ormond","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0470","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10730-024-09538-1","article-title":"The ethics of human embryo editing via CRISPR-Cas9 technology: a systematic review of ethical arguments, reasons, and concerns","volume":"37","author":"Wiley","year":"2025","journal-title":"HEC Forum"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0475","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41431-024-01740-6","article-title":"\u2018The DNA dialogues\u2019 consortium a decade of public engagement regarding human germline gene editing: a systematic scoping review","volume":"33","author":"Geuverink","year":"2025","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0480","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01608-8","article-title":"Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease","volume":"18","author":"Vallabh","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0485","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","article-title":"Towards a treatment for genetic prion disease: trials and biomarkers","volume":"19","author":"Vallabh","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0490","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002112","article-title":"Targeting AAV vectors to the central nervous system by engineering capsid\u2013receptor interactions that enable crossing of the blood\u2013brain barrier","volume":"21","author":"Huang","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0500","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0505","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12967-024-05661-2","article-title":"Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0510","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41436-021-01245-3","article-title":"Ethical challenges for a new generation of early-phase pediatric gene therapy trials","volume":"23","author":"Iyer","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0515","first-page":"730","article-title":"The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta\u2010analysis","volume":"11","author":"Forgrave","year":"2019","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0520","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaneurol.2019.1071","article-title":"Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease","volume":"76","author":"Staffaroni","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0525","doi-asserted-by":"crossref","first-page":"202","DOI":"10.12793\/tcp.2023.31.e21","article-title":"Adaptive design clinical trials: current status by disease and trial phase in various perspectives","volume":"31","author":"Lee","year":"2023","journal-title":"Transl. Clin. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0530","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1017\/cts.2023.537","article-title":"Recent innovations in adaptive trial designs: a review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J. Clin. Transl. Sci."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0535","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.18609\/cgti.2023.191","article-title":"US FDA perspective: preparing for a bright and busy future for cell & gene therapy","volume":"09","author":"Marks","year":"2023","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.neuroscience.2026.06.004_b0540","unstructured":"Administration, D., 2023. United States Department of Health and Human Services Food and Drug Administration FDA CBER OTAT Town Hall: Clinical Development of Gene Therapy Products for Rare Diseases."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0545","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuroscience.2026.06.004_b0550","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226003696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226003696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:11:30Z","timestamp":1784131890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226003696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":110,"alternative-id":["S0306452226003696"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.06.004","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current genetic approaches for the treatment of prion diseases","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}